Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

Background and Objective The interleukin-36 signalling pathway is associated with pathogenesis of a number of inflammatory diseases. Spesolimab is a selective, humanised, IgG1 antibody that targets the interleukin-36 receptor. We aimed to evaluate the pharmacokinetics, safety and tolerability of sin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics Jg. 61; H. 12; S. 1771 - 1787
Hauptverfasser:	Joseph, David, Thoma, Christian, Haeufel, Thomas, Li, Xiujiang
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.12.2022 Springer Nature B.V
Schlagworte:	Antibodies Cytokines Dermatitis Dose-Response Relationship, Drug Double-Blind Method Drug dosages Half-Life Healthy Volunteers Humans Inflammatory diseases Infusions, Intravenous Injections, Subcutaneous Internal Medicine Laboratories Medicine Medicine & Public Health Monoclonal antibodies NCT NCT02525679 NCT02852824 NCT03100903 NCT03123094 NCT03617835 Original Original Research Article Pathogenesis Pharmacokinetics Pharmacology Pharmacology/Toxicology Pharmacotherapy Plasma United States > US
ISSN:	0312-5963, 1179-1926, 1179-1926
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!